The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer

Artur A. Serebrenik, Prokopios P. Argyris, Matthew C. Jarvis, William L. Brown, Martina Bazzaro, Rachel I. Vogel, Britt Erickson, Sun Hee Lee, Krista M. Goergen, Matthew J. Maurer,

Clinical Cancer Research · 2020 · 69 citations · 42 references

DOIFull text

Open access

Abstract

These studies demonstrate that APOBEC3B is overexpressed in a subset of CCOC and, contrary to initial expectations, associated with improved (not worse) clinical outcomes. A likely molecular explanation is that APOBEC3B-induced DNA damage sensitizes cells to additional genotoxic stress by cisplatin. Thus, APOBEC3B is a molecular determinant and a candidate predictive biomarker of the therapeutic response to platinum-based chemotherapy. These findings may have broader translational relevance, as APOBEC3B is overexpressed in many different cancer types.

References

42